USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad

The observation issued is neither a repeated observation nor related to data integrity, said company.

225
USFDA Form 483
USFDA Form 483

Last Updated on October 6, 2024 by The Health Master

The United States Food and Drug Administration (USFDA) conducted Good Manufacturing Practice (GMP) Inspection at Gland Pharma’s Dundigal facility in Hyderabad between July 3 and July 14, 2023.

The inspection was concluded with one observation on Form 483.

The corrective and preventive actions for this observation will be submitted to the USFDA within the stipulated period.

The observation issued is neither a repeated observation nor related to data integrity, said company.

In the month of June, USFDA conducted a pre-approval inspection (PAI) for seven products and Good Manufacturing Practice (GMP) inspection at the company’s Pashamylaram facility in Hyderabad between June 15 and June 27, 2023.

This observation was procedural in nature and the corrective and preventive actions for this observation will be submitted to the USFDA within the stipulated period.

The observation issued is neither a repeated observation nor related to data integrity, the drugmaker said.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news